New Issue: Orbital Catastrophe Ahead? Read Now

Cell Transplant Therapy Offers New Hope for Type 1 Diabetes

Scientists have successfully transplanted gene-edited insulin-producing cells into a man with type 1 diabetes—allowing him to make some of his own insulin without immunosuppressants.

Join Our Community of Science Lovers!

Carin Leong: What if people with type 1 diabetes could start making their own insulin?

Scientists have just taken a big step in that direction. They treated a patient with 80 million lab-made insulin-producing cells that are designed to hide from the immune system. This is the first time a cell transplant like this hasn’t triggered a rejection in a human, and researchers say that this opens exciting possibilities for treating diabetes and other autoimmune diseases in the future.

About two million people in the U.S. currently live with type 1 diabetes. It’s an autoimmune disease where the body mistakenly wipes out the cells in the pancreas that make insulin. Without this hormone, people have to rely on injections and pumps every single day to keep their blood sugar in check and avoid serious complications.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Scientists have tried replacing these insulin-producing cells before, but the body kept attacking them. And patients would need to take strong immune-suppressing drugs for life, which come with their own laundry list of side effects.

This time, researchers took donor cells and used the gene-editing technique CRISPR to deactivate two genes that normally flag the immune system to attack foreign cells while also boosting expression of a gene that discourages attacks by the body’s immune cells.

So 12 weeks after injecting these cells into the patient, they were still alive and making insulin in his body. Granted, it wasn’t a ton—about 7 percent of what he'd need to ditch insulin injections entirely. But experts say it’s a major milestone for his body to be producing even a little bit of insulin on its own and, most importantly, without the need for immunosuppressants. They’ll continue monitoring him over the next year and test higher doses of these edited cells. And if all goes well, this could potentially lead us toward a cure for type 1 diabetes.

Carin Leong is a documentary filmmaker based in New York. Her projects have received support from Field of Vision, the Singapore International Film Festival, IN-DOCS, and the Tribeca Film Institute. Her work has appeared in Scientific American, Hakai Magazine, and The Atlantic. She holds a master's degree in science journalism from Columbia University's Graduate School of Journalism and is also a graduate of New York University's Tisch School of the Arts.

More by Carin Leong

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe